Aminex Therapeutics raised $15.08 million to advance AMXT 1501 in combination with DFMO, an FDA-designated orphan drug regimen in clinical trials for the treatment of neuroblastoma, a rare and aggressive pediatric cancer of the nervous system.
Aminex Therapeutics raised $15.08 million to advance AMXT 1501 in combination with DFMO, an FDA-designated orphan drug regimen in clinical trials for the treatment of neuroblastoma, a rare and aggressive pediatric cancer of the nervous system.